Dr. Clotet received his MD at the Universitat Autònoma de Barcelona in 1976 and his PhD in 1981 for his investigations on surrogate markers for connective tissue diseases.
He is an associated professor of medicine at the Universitat Autònoma de Barcelona, he is the head of infectious diseases department and president of Fundació Lluita contra la Sida” (Fight against AIDS Foundation). Dr. Clotet is also the Director of the retrovirology laboratory at “IrsiCaixa” Foundation and professor of the “Chair of AIDS and related diseases” at the Universitat de VIC (UVic-UCC).
He was Head of the HIV Unit of the Hospital Germans Trias between 1987 and 2015, when he became Head of the Infectious Diseases Department. He is also Director of the Retrovirology Laboratory “IrsiCaixa” Foundation, since 1995, and President of the “Lluita contra la SIDA” Foundation since 1992. Since 2006, he is co-director of the HIVACAT project for the development of the AIDS vaccine in Catalonia, Spain. He is associated professor of Medicine at the Universitat Autònoma de Barcelona (UAB) since 1986, and Professor of the “Chair of AIDS and related diseases” at the University of VIC (UVic-UCC) since October 2013. Dr. Clotet was member of the steering committee of EuroSIDA (multicenter group for the study of AIDS in Europe) between 1994 and 2010. His retrovirology laboratory at “IrsiCaixa Foundation” is the reference lab for HIV resistance in Europe through EuroSIDA.
He has published more than 500 papers in international journals and he is co-director of the AIDS CYBERJOURNAL and has been member of the editorial board of AIDS Journal for 8 years.He has authored numerous chapters in retrovirology, and he has been an invited speaker at numerous international and national conferences.
Dr. Clotet’s team is composed by 150 people working at the clinics and at the lab focusing on HIV, immune system abnormalities and related infectious diseases, cancer, papiloma virus, metagenomics, hepatitis and NASH, and aging. Dr. Clotet has created 2 spin-offs, currently active, from IrsiCaixa: AELIX Therapeutics and AlbaJuna Therapeutics.